GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0042176113 | Thyroid | PTC | regulation of protein catabolic process | 231/5968 | 391/18723 | 4.76e-29 | 2.14e-26 | 231 |
GO:0031647113 | Thyroid | PTC | regulation of protein stability | 174/5968 | 298/18723 | 2.05e-21 | 4.05e-19 | 174 |
GO:0045732113 | Thyroid | PTC | positive regulation of protein catabolic process | 142/5968 | 231/18723 | 1.43e-20 | 2.38e-18 | 142 |
GO:0022604112 | Thyroid | PTC | regulation of cell morphogenesis | 165/5968 | 309/18723 | 2.60e-15 | 1.82e-13 | 165 |
GO:000020920 | Thyroid | PTC | protein polyubiquitination | 128/5968 | 236/18723 | 7.81e-13 | 3.65e-11 | 128 |
GO:0016049112 | Thyroid | PTC | cell growth | 225/5968 | 482/18723 | 4.75e-12 | 2.07e-10 | 225 |
GO:007093620 | Thyroid | PTC | protein K48-linked ubiquitination | 45/5968 | 65/18723 | 6.91e-10 | 2.08e-08 | 45 |
GO:003010020 | Thyroid | PTC | regulation of endocytosis | 108/5968 | 211/18723 | 3.92e-09 | 1.04e-07 | 108 |
GO:0001558111 | Thyroid | PTC | regulation of cell growth | 188/5968 | 414/18723 | 4.13e-09 | 1.09e-07 | 188 |
GO:004580720 | Thyroid | PTC | positive regulation of endocytosis | 58/5968 | 100/18723 | 6.11e-08 | 1.28e-06 | 58 |
GO:0010975110 | Thyroid | PTC | regulation of neuron projection development | 194/5968 | 445/18723 | 1.05e-07 | 2.08e-06 | 194 |
GO:190382815 | Thyroid | PTC | negative regulation of cellular protein localization | 64/5968 | 117/18723 | 2.61e-07 | 4.52e-06 | 64 |
GO:001635819 | Thyroid | PTC | dendrite development | 115/5968 | 243/18723 | 3.16e-07 | 5.35e-06 | 115 |
GO:004858819 | Thyroid | PTC | developmental cell growth | 106/5968 | 234/18723 | 1.07e-05 | 1.19e-04 | 106 |
GO:0010038112 | Thyroid | PTC | response to metal ion | 157/5968 | 373/18723 | 1.80e-05 | 1.86e-04 | 157 |
GO:006056018 | Thyroid | PTC | developmental growth involved in morphogenesis | 105/5968 | 234/18723 | 1.94e-05 | 1.98e-04 | 105 |
GO:199013817 | Thyroid | PTC | neuron projection extension | 81/5968 | 172/18723 | 2.07e-05 | 2.08e-04 | 81 |
GO:00488139 | Thyroid | PTC | dendrite morphogenesis | 69/5968 | 146/18723 | 7.12e-05 | 6.19e-04 | 69 |
GO:00065138 | Thyroid | PTC | protein monoubiquitination | 34/5968 | 67/18723 | 1.00e-03 | 5.98e-03 | 34 |
GO:003030718 | Thyroid | PTC | positive regulation of cell growth | 71/5968 | 166/18723 | 1.98e-03 | 1.06e-02 | 71 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0453020 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa05169110 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa04530110 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa04530211 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa04530310 | Esophagus | ESCC | Tight junction | 105/4205 | 169/8465 | 6.73e-04 | 2.23e-03 | 1.14e-03 | 105 |
hsa0412010 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0453014 | Liver | NAFLD | Tight junction | 33/1043 | 169/8465 | 4.52e-03 | 4.12e-02 | 3.32e-02 | 33 |
hsa0412011 | Liver | NAFLD | Ubiquitin mediated proteolysis | 44/1043 | 142/8465 | 2.59e-09 | 1.70e-07 | 1.37e-07 | 44 |
hsa0453015 | Liver | NAFLD | Tight junction | 33/1043 | 169/8465 | 4.52e-03 | 4.12e-02 | 3.32e-02 | 33 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NEDD4 | SNV | Missense_Mutation | novel | c.3618N>G | p.Asp1206Glu | p.D1206E | P46934 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
NEDD4 | SNV | Missense_Mutation | | c.3271N>G | p.His1091Asp | p.H1091D | P46934 | protein_coding | deleterious(0.03) | benign(0.05) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NEDD4 | SNV | Missense_Mutation | rs547250575 | c.280G>A | p.Glu94Lys | p.E94K | P46934 | protein_coding | deleterious(0.05) | probably_damaging(0.965) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEDD4 | SNV | Missense_Mutation | | c.1361N>A | p.Arg454Gln | p.R454Q | P46934 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
NEDD4 | SNV | Missense_Mutation | | c.2611C>T | p.Pro871Ser | p.P871S | P46934 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD |
NEDD4 | SNV | Missense_Mutation | novel | c.154N>T | p.Met52Leu | p.M52L | P46934 | protein_coding | tolerated(0.3) | benign(0) | TCGA-E2-A576-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
NEDD4 | SNV | Missense_Mutation | rs369468383 | c.358G>T | p.Asp120Tyr | p.D120Y | P46934 | protein_coding | deleterious_low_confidence(0) | benign(0.347) | TCGA-GM-A2DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | PD |
NEDD4 | SNV | Missense_Mutation | novel | c.3895G>C | p.Glu1299Gln | p.E1299Q | P46934 | protein_coding | tolerated(0.13) | benign(0.125) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NEDD4 | insertion | Frame_Shift_Ins | novel | c.2747_2748insCCCTGTCTCTACTAAAAATGCAAAAAAAATTAGTTGGG | p.Lys916AsnfsTer26 | p.K916Nfs*26 | P46934 | protein_coding | | | TCGA-BH-A0H9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
NEDD4 | insertion | Frame_Shift_Ins | novel | c.38_39insGATATTCTTGTGTTTCAGTGCATTTG | p.Ser14IlefsTer45 | p.S14Ifs*45 | P46934 | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |